Aldons J Lusis Selected Research

trimethylamine

1/2022	Gut microbe-targeted choline trimethylamine lyase inhibition improves obesity via rewiring of host circadian rhythms.
12/2021	Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.
1/2019	Genetic Deficiency of Flavin-Containing Monooxygenase 3 ( Fmo3) Protects Against Thrombosis but Has Only a Minor Effect on Plasma Lipid Levels-Brief Report.
12/2015	Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.
1/2015	Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis.
11/2014	γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO.
5/2013	Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aldons J Lusis Research Topics

Disease

91	Atherosclerosis 12/2021 - 01/2002
36	Obesity 01/2022 - 05/2002
25	Inflammation (Inflammations) 05/2022 - 05/2002
21	Insulin Resistance 01/2022 - 06/2003
17	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 05/2002
16	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 01/2002
13	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2021 - 01/2004
12	Heart Failure 01/2022 - 07/2010
11	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 02/2010 - 01/2002
9	Atherosclerotic Plaque (Atheroma) 12/2021 - 07/2008
9	Type 2 Diabetes Mellitus (MODY) 01/2021 - 04/2005
9	Hypertriglyceridemia 05/2013 - 01/2002
8	Non-alcoholic Fatty Liver Disease 01/2022 - 06/2015
8	Fibrosis (Cirrhosis) 12/2021 - 02/2015
8	Dyslipidemias (Dyslipidemia) 01/2021 - 01/2002
8	Hyperlipidemias (Hyperlipidemia) 01/2019 - 11/2002
7	Body Weight (Weight, Body) 12/2019 - 03/2006
6	Hypertrophy 12/2021 - 11/2014
6	Fatty Liver 01/2021 - 06/2004
5	Hypercholesterolemia 01/2021 - 01/2002
5	Hyperglycemia 01/2021 - 05/2006
5	Thrombosis (Thrombus) 01/2019 - 04/2002
5	Heart Diseases (Heart Disease) 10/2018 - 04/2011
4	Infections 01/2021 - 09/2004
4	Myocardial Infarction 03/2016 - 10/2008
3	Cardiomegaly (Heart Hypertrophy) 12/2021 - 02/2015
3	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021 - 10/2019
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 01/2019
3	Glucose Intolerance 01/2019 - 03/2009
3	Stroke (Strokes) 01/2017 - 05/2013
3	Coronary Disease (Coronary Heart Disease) 01/2013 - 04/2003
3	Vascular Calcification 08/2010 - 06/2002
2	Alcoholic Fatty Liver 05/2022 - 10/2019
2	Heart Injuries 01/2022 - 01/2020

Drug/Important Bio-Agent (IBA)

40	LipidsIBA 11/2021 - 04/2002
28	CholesterolIBA 01/2021 - 01/2002
22	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 05/2002
21	trimethyloxamine (trimethylamine N-oxide)IBA 01/2022 - 04/2011
21	Triglycerides (Triacylglycerol)IBA 10/2021 - 01/2002
17	Apolipoproteins E (ApoE)IBA 05/2022 - 04/2002
17	ApolipoproteinsIBA 01/2020 - 01/2002
15	Lipoproteins (Lipoprotein)IBA 01/2021 - 01/2002
14	Proteins (Proteins, Gene)FDA Link 12/2021 - 04/2004
14	Insulin (Novolin)FDA Link 02/2021 - 05/2002
13	LDL Receptors (LDL Receptor)IBA 01/2021 - 07/2002
10	Choline (Choline Chloride)IBA 01/2022 - 04/2011
9	EnzymesIBA 01/2022 - 04/2002
9	Aryldialkylphosphatase (Paraoxonase)IBA 10/2020 - 07/2002
8	oxidized low density lipoproteinIBA 12/2021 - 04/2002
8	Phospholipids (Phosphatides)FDA LinkGeneric 12/2018 - 06/2004
7	trimethylamineIBA 01/2022 - 05/2013
7	Biological ProductsIBA 11/2021 - 06/2004
6	CytokinesIBA 05/2022 - 08/2006
6	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2019 - 02/2015
6	Fatty Acids (Saturated Fatty Acids)IBA 12/2018 - 06/2004
6	Transcription Factors (Transcription Factor)IBA 01/2018 - 04/2004
5	CollagenIBA 12/2021 - 11/2014
5	dimethylaniline monooxygenase (N-oxide forming) (flavin-containing monooxygenase)IBA 01/2019 - 01/2013
5	Messenger RNA (mRNA)IBA 01/2014 - 06/2004
5	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 10/2008 - 07/2002
4	Hormones (Hormone)IBA 01/2022 - 03/2009
4	LigandsIBA 12/2021 - 05/2002
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2018
4	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2021 - 04/2004
4	HDL CholesterolIBA 01/2021 - 03/2013
4	Adenosine Triphosphate (ATP)IBA 01/2019 - 08/2012
4	Antisense OligonucleotidesIBA 01/2019 - 01/2015
4	Pharmaceutical PreparationsIBA 01/2018 - 08/2007
4	Apolipoproteins B (ApoB)IBA 02/2016 - 04/2002
4	ChromatinIBA 01/2016 - 08/2014
4	HDL LipoproteinsIBA 09/2013 - 01/2002
4	LDL CholesterolIBA 05/2008 - 04/2004
4	Apolipoprotein A-II (Apolipoprotein A2)IBA 04/2008 - 06/2003
3	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 10/2021 - 12/2006
3	Macrophage Colony-Stimulating FactorIBA 01/2021 - 02/2010
3	AntioxidantsIBA 01/2021 - 01/2011
3	Estrogen ReceptorsIBA 01/2020 - 02/2015
3	Particulate MatterIBA 12/2019 - 01/2007
3	Liver X ReceptorsIBA 01/2018 - 09/2002
3	Bile Acids and Salts (Bile Acids)IBA 04/2015 - 10/2004
3	Carnitine (L-Carnitine)FDA LinkGeneric 11/2014 - 05/2013
3	Oxidants (Oxidizing Agents)IBA 09/2013 - 09/2004
3	Peroxidase (Myeloperoxidase)IBA 09/2013 - 09/2004
3	Leptin ReceptorsIBA 01/2012 - 05/2002
3	Arachidonic Acid (Vitamin F)IBA 10/2008 - 01/2004
3	ThioredoxinsIBA 10/2008 - 04/2004
2	OxysterolsIBA 05/2022 - 06/2010
2	LeptinIBA 01/2022 - 01/2022
2	Branched-Chain Amino AcidsIBA 01/2022 - 01/2019
2	Amino Acids FDA Link 01/2022 - 07/2012
2	Mitochondrial DNA (mtDNA)IBA 01/2022 - 01/2020
2	CeramidesIBA 01/2022 - 01/2018
2	CatecholaminesIBA 01/2022 - 01/2017
2	Adenine FDA LinkGeneric 01/2022 - 12/2021
2	AcidsIBA 01/2022 - 06/2004
2	LyasesIBA 01/2022 - 10/2018
2	Sucrose (Saccharose)IBA 12/2021 - 01/2013

Therapy/Procedure

8	Therapeutics 01/2022 - 02/2010
5	Transplantation 01/2021 - 09/2002
2	Bariatric Surgery 01/2022 - 12/2018